An updated safety label for the constipation and irritable bowel syndrome (IBS) medication Amitiza with the addition of two new adverse reactions has been approved by the Food and Drug Administration (FDA). The new labeling will include that cases of syncope (temporary loss of consciousness due to a drop in blood pressure) and hypotension (abnormally low blood pressure) have been reported in patients treated with the drug. In most cases, syncope or hypotension have occurred in patients taking 24 mcg twice daily and some occurred within an hour after taking the first dose or subsequent doses. The new label states that ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.